Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study)

Next Previous
Trial Profile

A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 29 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Docetaxel
  • Indications Lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms Lung- Map Sub-Study

    • Most Recent Events

    • 01 Dec 2021 Status changed from active, no longer recruiting to completed.
    • 31 Jan 2021 Results (n=320) of an analysis assessing Tumor Mutation Burden and related biomarkers by NGS and determining associations with clinical outcomes using data from two clinical sub-studies: S1400I and S1400A presented at the 2020 World Conference on Lung Cancer
    • 13 Dec 2017 Planned End Date changed from 1 Apr 2027 to 1 Apr 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top